July 5, 2007 -- A Washington Post article, published today, looked at US cancer patients who are traveling to China to receive Gendicine, the gene therapy for cancer that is produced by Shenzhen SiBiono GeneTech in China, a company that is majority owned by Benda Pharma. The article structured the story around the argument that the treatments are yet another example of China ignoring the legitimate intellectual property rights of Western enterprises. In this case, according to the article, the aggrieved company is Introgen of Austin, Texas, which has been working for 15 years to bring a similar drug to market. We look at the charges and counter-charges...
